role of bcma in predicting outcomes and monitoring mm and cll
Published 4 years ago • 271 plays • Length 20:03Download video MP4
Download video MP3
Similar videos
-
20:03
bcma: predicting outcomes and monitoring mm and cll
-
17:20
b-cell maturation antigen: a new biomarker for b-cell malignancies
-
6:09
outcomes in rrmm: the modern treatment paradigm and bcma
-
20:43
r/r high risk cll: personalized management based on patient characteristics and cytogenetics
-
54:38
bcma antibodies and cellular therapies in rrmm
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
3:28
the importance of bcma-targeting adcs and bispecific antibodies in r/r multiple myeloma
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
1:48
mechanisms behind the loss of bcma in multiple myeloma & options for patients
-
11:01
targeting bcma for r/r myeloma
-
1:07
car t-cells directed against bcma in mm
-
3:10
bcma: a new biomarker for multiple myeloma
-
0:58
novel car-t constructs emerging in multiple myeloma for patients who experience loss of bcma
-
3:54
predictors of t cell expansion and clinical responses following cart-bcma for rrmm
-
2:34
bcma
-
1:05
novel car-t constructs emerging for patients with multiple myeloma who experience loss of bcma
-
21:39
car-ts: what are the next generation products and strategies?
-
18:55
combinations of myeloma: should second and third line agents be used upfront?
-
29:26
predicting outcomes in ra - the role of biomarkers